I Don't Want To Put Him Through ThisMarch 1, 201003/15/2010 - Who cares about the diagnosis? 03/01/2010 - Feed Them and They Will Come 02/12/2010 - Dealing With (Mis)guidance The most common line to decline surgery in my practice is "Yeah, well … I don't want to put him through this." To be fair, it probably means different things to different people. The vast majority of the time, I suspect that it means, "There is no way I'm spending that kind of money on this mutt." Sometimes, it means that the owner is truly concerned about how invasive surgery is. A classic example is amputation. Pet owners invariably unconsciously anthropomorphize and just can't imagine themselves hopping on one leg. Of course, we know better. I have never seen a three-legged patient not walk. Even with DJD in the remaining limbs. I have had my own doubts and hesitations. Colleagues, surgeons and oncologists questioned over the years have all agreed. They have never seen a three-legged patient not walk. Surely, there must be exceptions. The same reasoning applies to mandibulectomies and maxillectomies. They typically sound horrifying to clients (and some referring vets). Yet surgeons are often amazed that their patient will most of the time eat the very next day after surgery. …
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
Feed Them And They Will ComeMarch 1, 201002/12/2010 - Dealing With (Mis)guidance 02/01/2010 - Anesthesia: It Ain't Over Till It's Over 01/18/2010 - Who should euthanize Leia? Let me share a little secret with you. "Feed them and they will come" is what speakers and sponsors say about you, dear reader. Please don't tell anyone. It's a secret. A referring vet once told me, half-jokingly: "It's really strange. Young surgeons who have more energy and time, but less experience, are the one giving all the talks. Senior surgeons who have less energy and time, but more experience, are the ones who rarely give talks." Likewise, an executive at our local veterinary medical association recently noticed: "It's really strange. Young vets who have less knowledge and experience rarely join us for CE meetings. Senior vets who have more knowledge and experience are the ones who show up routinely." We began trying to understand what it would take for our young local colleagues to join us. This is what we have to offer: • Great speakers from various specialties and practices, sometimes from out of state, eager to share their knowledge. • Generous sponsors who provide great food and information about new products and services. • An open forum to discuss difficult …
Study Finds Alternative Antiviral For Bird Flu Prevention And TreatmentFebruary 26, 2010 New research out of the University of Wisconsin-Madison School of Veterinary Medicine reveals that a novel compound proves highly effective against the pathogenic H5N1 avian influenza virus. The study, led by virologist Yoshihiro Kawaoka, professor of pathobiological sciences, appeared in the Public Library of Science journal PLoS Pathogens on Feb. 26. It suggests that the compound CS-8958 is a promising alternative antiviral for prevention and treatment of bird flu. Antiviral drugs are a key countermeasure against human influenza viruses, according to the university. This includes the pathogenic H5N1 avian influenza virus, which causes bird flu. The emerging strains resistant to existing drugs, particularly oseltamivir (Tamiflu), make the development of alternate antivirals a public health issue, Kawaoka said. He and researchers from Japan, Vietnam and Indonesia tested a neuraminidase inhibitor R-125489 and its prodrug CS-8958, which had previously shown potent activity against seasonal influenza viruses in laboratory animals. Working with mice, the researchers learned that a single intranasal dose of CS-8958 given two hours after infection with H5N1 influenza virus resulted in a higher survival rate and lower virus levels than a standard five-day course of oseltamivir. CS-8958 was also effective against highly pathogenic and oseltamivir-resistant …
Researcher Combines Computers, Biology To Track FluFebruary 25, 2010 An assistant professor in systems biology at Mississippi State University’s College of Veterinary Medicine has combined computers and biology to track animal flu viruses. During graduate studies in China, Henry Wan, DVM, MS, Ph.D., became the first scientist to isolate the highly pathogenic H5N1 avian influenza virus, according to MSU. Shortly after, highly pathogenic H5N1 outbreaks occurred in poultry in Asia, Europe and Africa. More than 440 confirmed human cases across 15 countries were caused by the virus. About 60 percent of them were fatal. “My research centers on influenza A viruses," Dr. Wan said. "Where they come from, why they change and how they spread.” He developed computer programs that provide information on each one of the more than 20,000 viruses’ gene segments, according to MSU. The program displays each gene segment and a map showing the distances between the segments. The information is used to determine how the segments relate to each other and group to form different influenza viruses, which are always changing, Wan said. “The program aims to seek a better understanding of why they mutate and how they spread," he said. "Knowing this helps us more …
Abaxis Reports Record RevenuesFebruary 25, 2010Abaxis Inc., manufacturer of point-of-care blood analysis systems to the medical and veterinarian markets, has reported record financial growth for the fiscal quarter ended Dec. 31, 2009. The company reported veterinary market sales of $23.9 million, a 33 percent gain over last year’s comparable quarter. The company also reported total medical and veterinary instrument sales of 1,212 units, up 37 percent over the same period last year. Quarterly highlights also include total medical and veterinary reagent disc sales of $16.3 million, up 5 percent over last year’s comparable quarter. Consumables revenue, which includes heartworm rapid tests, increased by an aggregate of $3.4 million, or 20 percent, over the same period last year. Clint Severson, chairman and CEO of Abaxis, said the company has posted another solid quarter of double-digit growth accompanied with strong operating margins. Revenues grew 15 percent to a record $31 million for the quarter, led by a 37 percent increase in instrument unit sales. “Our balance sheet remains healthy with $93.2 million in cash, cash equivalents, short- and long-term investments and no long-term debt,” Severson said. <HOME>
Veterinarians Invited To Horse Stem Cell Conference In CaliforniaFebruary 24, 2010 Researchers and veterinary practitioners from throughout the United States and abroad are invited to the inaugural North American Veterinary Regenerative Medicine Conference, a two-day event to include scientific presentations, demonstrations and discussion sessions. The meeting is coordinated by the UC Davis Center for Equine Health and the Alamo Pintado Equine Medical Center in California’s Central Coast. The groundbreaking conference on the use of stem cell therapy and regenerative medicine to treat horses and other animals will feature new research developments and techniques for harvesting, expanding and preserving stem cells, according to the university. In addition, the 200 expected participants will learn about clinical applications and methods for using stem cells in orthopedics, including treating tendon and ligament injuries. One roundtable session plans to feature a discussion on the use of regenerative medicine in equine veterinary practices. Live demonstrations at the equine medical center are set to highlight stem cell collection techniques from bone marrow and fat, and laboratory processing of bone marrow samples, organizers said. The UC Davis Center for Equine Health is coordinating a regenerative medicine research study, now in its fourth year. The study is led by a team of 20 university researchers, including …
Heska Reports Fourth Quarter ProfitsFebruary 22, 2010 Heska Corporation of Loveland, Colo., which sells advanced veterinary diagnostic and other specialty veterinary products, reported fourth-quarter net income of $460 thousand or $0.01 per share, compared with a net loss of $1.9 million or $0.04 per share in the year-ago period. The company reported fourth-quarter net revenue in core companion animal health products of $17.4 million, a 6 percent increase from the year-ago period. Heska cited its heartworm-related products as a reason for the increase. For the 12-month period ended Dec. 31, 2009, the company reported revenue for this category of $75.7 million, compared with net revenue of $81.7 million in the year-ago period. For the year, Heska reported more than $4 million in operating income - the second best result in company history, despite a challenging economic environment, said Robert Grieve, Heska’s chairman and CEO. “In the fourth quarter of 2009, we produced revenue growth in both of our operating segments, increased our gross margin and decreased our operating expenses compared to the fourth quarter of 2008,” Grieve said. “We also placed our first Dri-Chem 7000 Veterinary Chemistry Analyzers with our customers in the fourth quarter of 2009.” The company continues to be …
VCA Antech Reports Fourth Quarter EarningsFebruary 19, 2010 Animal healthcare company VCA Antech Inc. of Los Angeles, Calif. has reported that financial results for the fourth quarter ended Dec. 31, 2009 show revenue increased 4 percent to $315.2 million, net income decreased 1.3 percent to $25.4 million and diluted earnings per common share was $0.29. Results for the year ended Dec. 31, 2009 include the following: revenue increased 2.9 percent to a record $1.31 billion; gross profit increased slightly to $343.0 million; net income decreased 1.2 percent to $131.4 million; and diluted earnings per common share was at $1.53. Twelve-month results include a charge, net of the recovery in the fourth quarter, of $2 million or $0.02 per diluted share related to abandonment of an internally developed software project. Excluding this item, adjusted net income increased slightly to $133.5 million and adjusted diluted earnings per common share remained flat at $1.55. Bob Antin, chairman and CEO, said the company faced challenges in 2009. “As with most companies, the economy negatively impacted our revenue growth rates throughout the year. While the economy continues to put pressure on us, we have seen a relative improvement in the fourth quarter in comparison to the previous three quarters,” he said. …
Pfizer Animal Health Program Contributes $1.3 Million To FFA In 2009February 19, 2010 New York, N.Y.-based Pfizer Animal Health said it plans to continue a contribution program that raised more than $1.3 million in 2009 for Future Farmers of America programs and veterinary scholarships through a partnership with veterinarians, animal health suppliers and dealers. This gives customers a second opportunity to donate in 2010 and help fund the American Association of Bovine Practitioners (AABP) Foundation/Pfizer Veterinary Student Scholarships and FFA programs, Pfizer said. This opportunity is available now through March 31. During this time, eligible accounts completing an enrollment form get a 1 percent rebate on Pfizer Animal Health Cattle Products, excluding MGA purchases, invoiced and shipped Jan. 1 through March 31 to be donated to either the local FFA chapter(s) of their choice or to the AABP Foundation/Pfizer Veterinary Student Scholarship Fund. Will Fett, National FFA Foundation regional director, said these contributions help strengthen local FFA chapters and expand offerings available to students. “Just as important, members are able to make connections with their local animal health professionals,” he said. In 2009, more than 1,160 Pfizer Animal Health suppliers contributed to FFA chapters. In addition, the program raised more than $212,400 for the AABP Foundation scholarships. …
Andis Pet Grooming Supplier Expands OperationsFebruary 17, 2010Andis Company, a manufacturer of handheld tools for animal groomers, plans to develop a 50,000 square foot expansion of its headquarters, at 1800 Renaissance Blvd., Sturtevant, Wis. The growth, the company said, adds space for manufacturing and warehousing, while generating job opportunities. The project is expected to be completed by the end of this summer. Matthew Andis, executive vice president, said the company has called Racine County home for 88 years. “Partnering with the village of Sturtevant, we look forward to fostering our mission to create value for our customers, community and families; fulfill our passion for growth; and fuel our dedication to legacy,” he said in a statement. Andis Company’s facilities house office space, plus manufacturing, assembly, and distribution operations in more than 107,000 square feet. The expansion takes place on the south side of the building to provide easy product flow, the company said. <HOME>
